S-Equol is the only enantiomer that binds strongly to estrogen receptor beta (ERβ). It is produced in the gut of about 25–30% of the population (equol producers). Synthetic S-Equol allows consistent, standardized dosing for products that target hormone balance, menopause, skin aging and prostate health.

Equol is one of the primary metabolites of daidzein produced by gut microbiota. It exists as two distinct enantiomers: S-equol and R-equol. Notably, only 20–30% of adults possess the specific gut flora required to produce equol naturally, and the human body exclusively generates the S-form.

The biological activities of these two enantiomers differ significantly. S-equol exhibits a high binding affinity for estrogen receptor beta (ERβ), making it particularly advantageous for bone health and menopausal support. In contrast, R-equol demonstrates superior benefits in skincare applications.

LyvBio now offers both S-equol and racemic SR-equol ingredients. As the global women’s health market expands rapidly, these enantiomers hold immense potential for precision-based applications—whether used individually for targeted functions or combined to achieve more comprehensive wellness outcomes.

Equol is one of the primary metabolites produced through the biotransformation of daidzein by the gut microbiota following dietary intake. Unlike other soy isoflavones such as daidzein or genistein, equol possesses a chiral center, allowing it to exist as two distinct enantiomers: R-equol and S-equol.

Research indicates that only approximately 20–30% of adults are capable of producing equol after consuming soy-based foods. This specific subset of the population is referred to as “equol producers,” whereas non-producers lack the specific gut flora required to catalyze this conversion. This pronounced inter-individual variability in equol production is closely linked to the composition of the gut microbiome, underscoring the significant clinical relevance of equol-related research.

LyvBio supplies both S-equol and SR-equol

LyvBio supplies both S-equol and SR-equol, allowing customers to choose based on their needs and budget. S-equol comes at a premium cost, while SR-equol offers a more competitive price-performance ratio. The choice ultimately depends on the specific product positioning and desired health outcomes.

R-equol and S-equol exhibit distinct, division-of-labor characteristics across multiple biological dimensions. As outlined in the comparison above, the advantage of S-equol lies primarily in its highly selective activation of estrogen receptor beta (ERβ) and the subsequent downstream effects. These properties endow S-equol with significant application potential in estrogen-related health arenas, particularly in bone health and menopausal support.

As a natural metabolite produced by the human gut microbiota, S-equol has already been developed into dietary supplements specifically targeting menopausal wellness and skeletal integrity.

Supplier: LyvBio Co., Ltd.

LyvBio Co., Ltd. is a GMP-certified supplier of high-purity Equol for research and development applications.

Supply capabilities:

• Assay (HPLC): , ≥98.0% (high purity)

• Appearance: white fine powder

• Monthly capacity: 500g – 1kg

• Bulk quantities: 100mg – 500g

• Lead time: 3–5 days (samples), 10–15 days (bulk)

• Documentation: COA, MSDS, TDS, HPLC chromatogram, NMR (upon request), stability data